Guanfacine ER for the treatment of adolescent attention-deficit/ hyperactivity disorder

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 15, 2012, Pages 2207-2213

  Bukstein, Oscar Gary ^a   Head, Jared ^b  

^a WPIC   (United States)

^b UTHSC Houston   (United States)

Author keywords

2 adrenoceptor agonist; ADHD; Attention deficit hyperactivity disorder; Guanfacine

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; CLONIDINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GUANFACINE; PLACEBO; PSYCHOSTIMULANT AGENT;

ADJUVANT THERAPY; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; FATIGUE; HEADACHE; HUMAN; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; PHARMACODYNAMICS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DELAYED-ACTION PREPARATIONS; GUANFACINE; HUMANS;

EID: 84866521006     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.721778     Document Type: Review

References (48)

1. Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3rd edition. Guilford Press; New York, NY: 2006
2. Fischer M, Barkley R, Fletcher K, et al. The stability of dimensions of behavior in ADHD and normal children over an 8-year followup. J Abnorm Child Psychol 1993;21:315-37 (Pubitemid 23177513)
3. Hart E, Lahey B, Loeber R, et al. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 1995;23(6):729-49
4. Molina B, Hinshaw S, Swanson J, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500
5. Willoughby M. Developmental course of ADHD symptomatology during the transition from childhood to adolescence: a review with recommendations. J Child Psychol Psychiatry 2003;44:88-106 (Pubitemid 36943951)
6. Sibley MH, Pelham WE Jr, Molina BS, et al. Diagnosing ADHD in adolescence. J Consult Clin Psychol 2012;80(1):139-50
7. Sibley MH, Pelham WE, Molina BSG, et al. The delinquency outcomes of boys with ADHD with and without comorbidity. J Abnorm Child Psychol 2011;39:21-32
8. Kent KM, Pelham WE, Molina BSG, et al. The academic experience of male high school students with ADHD. J Abnorm Child Psychol 2011;39:451-62
9. Flory K, Molina B, Pelham W, et al. Childhood ADHD predicts risky sexual behavior in young adulthood. J Clin Child Adolesc Psychol 2006;35:571-7 (Pubitemid 44759736)
10. Molina BSG, Pelham WE, Gnagy EM, et al. Attention-deficit/hyperactivity disorder risk for heavy drinking and alcohol use disorder is age specific. Alcoholism 2007;31:643-54 (Pubitemid 46434901)
11. Thompson A, Molina B, Pelham W, et al. Risky driving in adolescents and young adults with childhood ADHD. J Pediatr Psychol 2007;32:745-59 (Pubitemid 47216582)
12. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010;70:15-40
13. Kapvay [package insert]. Shionogi Pharma, Inc; Atlanta, GA: 2010
14. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
15. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2):26S-S49S
16. Faraone SV, Pucci M, Coghill D. Pharmacotherapy for attention deficithyperactivity disorder. US Psychiatry Rev 2009;2:17-27
17. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention deficithyperactivity disorder. N Engl J Med 1999;340:780-8
18. Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo- controlled trial. Arch Gen Psychiatry 1997;54:857-64 (Pubitemid 27383313)
19. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: multimodal treatment study of children with ADHD. Arch Gen Psychiatry 1999;56:1073-86
20. Wilens TE, Spencer T, Biederman J, et al. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1995;34:110-12
21. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001;40:168-79 (Pubitemid 32111020)
22. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006;28:1892-908 (Pubitemid 46038524)
23. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994;148(8):859-61 (Pubitemid 24243781)
24. Barkley R, Fischer M, Edelbrock C, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990;29:546-57 (Pubitemid 20235340)
25. Sorkin EM, Heel RC. Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1986;31:301-36 (Pubitemid 16167001)
26. Newcorn JH, Schulz K, Harrison M, et al. Alpha 2 adrenergic agonists: neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am 1998;45:1099-22.viii
27. Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention- deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995;5:215-23
28. Kugler J, Seus R, Krauskopf R, et al. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol 1980;10(Suppl 1):71S-80S (Pubitemid 10065114)
29. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha- 2 receptor subtypes. J Neurosci 1988;8:4287-98 (Pubitemid 19017410)
30. Uhlen S, Wikberg JE. Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H] RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol 1991;202:235-43
31. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995;34:1134-46
32. Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995;5:215-23
33. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-4
34. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-74 (Pubitemid 32623110)
35. Intuniv [package insert]. Shire Pharmaceuticals, Inc; Wayne, PA: 2011
36. Boellner SW, Pennick M, Shojaei A, et al. Pharmacokinetics of Guanfacine Extended Release in Children and Adolescents With ADHD. Poster, presented at Presented at the 58th Institute on Psychiatric Services; 6 October 2006; New York, NY
37. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121(1):73-84
38. Sallee F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-65
39. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012;51(1):74-85
40. Bukstein O, Turnbow JM, Youcha S, et al. Efficacy and Safety of Morning or Evening Administration of Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Adolescents With ADHD. Presented at the 164th Annual Meeting of the American Psychiatric Association; 14 - 18 May 2011; Honolulu, Hawaii
41. Biederman J, Melmed RD, Patel A, et al. Long-term open-label extension study of guanfacine extended release in chailren and adolescents with ADHD. CNS Spectr 2008;13:1047-55
42. Pediatric Post-marketing Adverse Event Review for Intuniv -. Washington DC: FDA/Center for Drug Evaluation and Research, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM255105.pdf?utm- campaign=Google2&utm- source=fdaSearch&utm- medium=website&utm-term=guanfacine aers&utm-content=1 [Last Accessed 10 June 2012]
43. Biederman J, Lyne A, Sallee FR, et al. Efficacy and Safety of Guanfacine Extended Release in Attention-Deficit/Hyperactivity Disorder. Presented at the 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry; 23 - 28 October 2007; Boston, Massachusetts
44. Fasmer OB, Halmøy A, Oedegaard KJ, et al. Adult attention deficit hyperactivity disorder is associated with migraine headaches. Eur Arch Psychiatry Clin Neurosci 2011;261(8):595-602
45. Antonaci F, Nappi G, Galli F, et al. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain 2011;12(2):115-25
46. Search Of: guanfacine - List Results - ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/results? term=guanfacine [Last Accessed 13 June 2012]
47. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. CNS Drugs 2010;24(9):755-68
48. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-85 (Pubitemid 43848299)